TRDA
Entrada Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.13
−0.56%Year over year
Reported trailing growth
- Revenue
- -94.1%
- EBITDA
- -96.5%
- EBIT
- -83.6%
- EPS
- —
- Free cash flow
- -6.2%
- Operating cash flow
- -8.7%
Forward estimates
Based on analyst estimates
- Revenue
- +400.3%
- EBITDA
- +11.4%
- EPS
- +11.0%
Three-year CAGR
- Revenue
- -55.6%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026